Newest Threat to Medical Freedom—Monkeypox “Emergency” by Elizabeth Lee Vliet, MD via Health Impact News
The World Health Organization declaration of Monkeypox as a “Public Health Emergency of International Concern” (PHEIC), was made by one man, WHO Director-General Tedros Adhanom Ghebreyesus, who has no medical training, over the objection of the majority of his own expert committee of medical and scientific advisors. Nine of the committee members thought a PHEIC should not be declared and six supported a declaration.
“Nine and six is very, very close. Since the role of the committee is to advise, I decided to act as a tie-breaker,” Tedros said in a news conference called to announce the decision.”
Perhaps it is the “new math” that leads to the conclusion of a “tie” with a 3-vote majority on one side? And why did Tedros decide to go with the minority opinion rather than the majority?
Rosamund Lewis, the WHO technical lead for monkeypox, said in a July 20 press conference: “About 98 percent of (Monkeypox) cases are among men who have sex with men—and primarily those who have multiple recent anonymous or new partners.” She then said they are typically young and chiefly live in urban areas.
So why did Tedros decide unilaterally to declare a global emergency for the vast majority of people who do not fit this profile?
A little-known fact about the PHEIC designation is that it triggers implementation of the International Health Regulations signed in 2005 by more than 190 countries. It seems evident that WHO plans to continue their power, implemented with the COVID emergency declaration, to dictate global public health policy, and their directives for oppressive measures such as lockdowns and travel restrictions that WHO pushed globally during COVID. Since COVID obviously wasn’t stopped, WHO appears determined to implement still more draconian measures, and push more coercive vaccine mandates.
Conveniently, shortly just before the monkeypox scare, Bavarian Nordic’s JYNNEOS vaccine was approved by the FDA in September 2019 for use against both smallpox and its cousin monkeypox. This is in spite of published data showing JYNNEOS product is associated with higher risk of myocarditis, also a serious risk with the COVID shots.